Journal of Interventional Cardiology / 2022 / Article / Tab 1 / Research Article
Clinical Effect of Revascularization Strategies and Pharmacologic Treatment on Long-Term Results in Patients with Advanced Peripheral Artery Disease with TASC C and D Femoropopliteal Lesions Table 1 Baseline demographics and characteristics associated with intervention.
Characteristic Total population (n = 187) EVT group (n = 94) Bypass group (n = 93) valueAge (years) 75.1 ± 11.9 75.8 ± 13.4 74.4 ± 10.3 0.424 BMI 23.4 ± 4.4 24 ± 3.7 22.8 ± 5.0 0.079 SBP 137.1 ± 24.1 137.1 ± 24.1 137.1 ± 24.2 0.988 Gender (female) 52 (27.8) 26 (27.7) 26 (28.0) 0.964 Lesion site (left) 91 (48.7) 45 (47.9) 46 (49.5) 0.828 Baseline CAD 71 (38) 34 (36.2) 37 (39.8) 0.611 ESRD (regular dialysis) 66 (35.6) 36 (38.3) 30 (32.3) 0.388 DM 112 (59.9) 61 (64.9) 51 (54.8) 0.161 Hypertension 154 (82.4) 76 (80.9) 78 (83.9) 0.588 Hyperlipidemia 51 (27.3) 25 (26.6) 26 (28.0) 0.321 Baseline CVA 24 (12.8) 15 (16) 9 (9.7) 0.199 Smoking 75 (40.3) 35 (37.6) 40 (43.0) 0.455 Cellulitis on presentation 145 (77.5) 74 (78.7) 71 (76.3) 0.697 Atrial fibrillation 14 (7.5) 9 (9.6) 5 (5.4) 0.275 Baseline ABI 0.52 ± 0.13 0.51 ± 0.11 0.53 ± 0.16 0.473 Calcification 75 (43.6) 36 (42.4) 39 (44.8) 0.744 Retinopathy 28 (15) 18 (19.1) 10 (10.8) 0.108 Neuropathy 49 (26.2) 29 (30.9) 20 (21.5) 0.146 Rutherford classification 0.757 Stage III 17 (9.1) 10 (10.6) 7 (7.5) Stage IV 41 (21.9) 20 (21.3) 21 (22.6) Stage V plus VI 129 (69) 64 (68.1) 65 (66.9) hsCRP (mg/L) 4.85 ± 5.23 4.45 ± 4.99 5.28 ± 5.49 0.297 HA1c (%) 7.51 ± 1.57 7.57 ± 1.57 7.43 ± 1.59 0.659 Concomitant medications OHA alone 65 (37.8) 27 (31.8) 38 (43.7) 0.107 Insulin alone 55 (29.4) 30 (31.9) 25 (26.9) 0.450
ABI: ankle brachial index; BMI: body mass index; SBP: systolic blood pressure; CAD: coronary artery disease; CVA: cerebral vascular accident; DM: diabetes mellitus; ESRD: end-stage renal disease; EVT, endovascular therapy; hsCRP: high-sensitivity C-reactive protein; HA1c: hemoglobin A1c; OHA, oral hypoglycemic agent.